| Drug Name | ( VOTRIENT (Pazopanib |
|---|---|
| Drug Class |
Anticancer
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Oncology
|
| Risk |
Important change to frequency of Serum liver test monitoring for hepatotoxicity |
| Dear Healthcare provider letter DHPC |
|